A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol - Report - MDSpire
Advertisement
A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol
Clinical Report: Safety and Effectiveness of LivaloZet® in Dyslipidemia
Overview
The PIVOT study aims to evaluate the safety and effectiveness of LivaloZet® tablets in Korean adults with dyslipidemia and metabolic syndrome. The primary endpoint is the change in LDL-C levels at 24 weeks, with secondary endpoints including lipid panel changes and glucose metabolism parameters.
Background
Dyslipidemia and metabolic syndrome significantly increase cardiovascular risk, necessitating effective lipid-lowering therapies. LivaloZet® combines pitavastatin and ezetimibe, targeting cholesterol reduction while maintaining a favorable metabolic profile.
Data Highlights
No numerical data available in the source material.
Key Findings
The PIVOT study is a multicenter, open-label observational trial.
It will enroll up to 10,000 Korean adults with dyslipidemia and metabolic syndrome.
The primary endpoint is the percent change in LDL-C from baseline at Week 24.
Secondary endpoints include changes in the full lipid panel and LDL-C target achievement rates.
Safety assessments will include monitoring for hepatotoxicity and myopathy.
Clinical Implications
The PIVOT study will provide real-world evidence on the effectiveness and safety of LivaloZet® in a large cohort of patients. Understanding the metabolic safety profile of this combination therapy is crucial for managing dyslipidemia in patients with metabolic syndrome.
Conclusion
The findings from the PIVOT study will contribute to the understanding of lipid-lowering therapies in patients with dyslipidemia and metabolic syndrome, particularly in the Korean population.
From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.
